Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Targeted therapies: Time to shift the burden of proof for oncogene-positive cancer?

Literature DB >> 23881038

Targeted therapies: Time to shift the burden of proof for oncogene-positive cancer?

Abstract

Rearrangements of the ALK gene have been associated with sensitivity to crizotinib and other kinase inhibitors with activity against ALK. The phase III PROFILE 1007 randomized study of crizotinib versus chemotherapy has demonstrated that crizotinib is superior to standard second-line chemotherapy in ALK-positive non-small-cell lung cancer.

Entities: Chemical Disease Gene

Mesh：

Substances：

Year: 2013 PMID： 23881038 DOI： 10.1038/nrclinonc.2013.135

Source DB: PubMed Journal: Nat Rev Clin Oncol ISSN： 1759-4774 Impact factor: 66.675

8 in total

Review 1. Treating ALK-positive lung cancer--early successes and future challenges.

Authors: D Ross Camidge; Robert C Doebele
Journal: Nat Rev Clin Oncol Date: 2012-04-03 Impact factor: 66.675

2. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed.

Authors: D Ross Camidge; Scott A Kono; Xian Lu; Sonia Okuyama; Anna E Barón; Ana B Oton; Angela M Davies; Marileila Varella-Garcia; Wilbur Franklin; Robert C Doebele
Journal: J Thorac Oncol Date: 2011-04 Impact factor: 15.609

Review 3. Molecular pathways: ROS1 fusion proteins in cancer.

Authors: Kurtis D Davies; Robert C Doebele
Journal: Clin Cancer Res Date: 2013-05-29 Impact factor: 12.531

4. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

Authors: Tony S Mok; Yi-Long Wu; Sumitra Thongprasert; Chih-Hsin Yang; Da-Tong Chu; Nagahiro Saijo; Patrapim Sunpaweravong; Baohui Han; Benjamin Margono; Yukito Ichinose; Yutaka Nishiwaki; Yuichiro Ohe; Jin-Ji Yang; Busyamas Chewaskulyong; Haiyi Jiang; Emma L Duffield; Claire L Watkins; Alison A Armour; Masahiro Fukuoka
Journal: N Engl J Med Date: 2009-08-19 Impact factor: 91.245

5. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies.

Authors: Giorgio Scagliotti; Nasser Hanna; Frank Fossella; Katherine Sugarman; Johannes Blatter; Patrick Peterson; Lorinda Simms; Frances A Shepherd
Journal: Oncologist Date: 2009-02-16

6. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Authors: Alice T Shaw; Dong-Wan Kim; Kazuhiko Nakagawa; Takashi Seto; Lucio Crinó; Myung-Ju Ahn; Tommaso De Pas; Benjamin Besse; Benjamin J Solomon; Fiona Blackhall; Yi-Long Wu; Michael Thomas; Kenneth J O'Byrne; Denis Moro-Sibilot; D Ross Camidge; Tony Mok; Vera Hirsh; Gregory J Riely; Shrividya Iyer; Vanessa Tassell; Anna Polli; Keith D Wilner; Pasi A Jänne
Journal: N Engl J Med Date: 2013-06-01 Impact factor: 91.245

7. Acquired resistance to crizotinib from a mutation in CD74-ROS1.

Authors: Mark M Awad; Ryohei Katayama; Michele McTigue; Wei Liu; Ya-Li Deng; Alexei Brooun; Luc Friboulet; Donghui Huang; Matthew D Falk; Sergei Timofeevski; Keith D Wilner; Elizabeth L Lockerman; Tahsin M Khan; Sidra Mahmood; Justin F Gainor; Subba R Digumarthy; James R Stone; Mari Mino-Kenudson; James G Christensen; A John Iafrate; Jeffrey A Engelman; Alice T Shaw
Journal: N Engl J Med Date: 2013-06-01 Impact factor: 91.245

8. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

Authors: D Ross Camidge; Yung-Jue Bang; Eunice L Kwak; A John Iafrate; Marileila Varella-Garcia; Stephen B Fox; Gregory J Riely; Benjamin Solomon; Sai-Hong I Ou; Dong-Wan Kim; Ravi Salgia; Panagiotis Fidias; Jeffrey A Engelman; Leena Gandhi; Pasi A Jänne; Daniel B Costa; Geoffrey I Shapiro; Patricia Lorusso; Katherine Ruffner; Patricia Stephenson; Yiyun Tang; Keith Wilner; Jeffrey W Clark; Alice T Shaw
Journal: Lancet Oncol Date: 2012-09-04 Impact factor: 41.316